Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,822 across all filing types
Latest filing 2021-04-06 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2021-04-06 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document text consists almost entirely of tabular data showing 'Volume', 'Price', 'Venue' (XCSE), and 'Time CET'. The entries are numerical codes (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 35, 36, 38, 39, 43, 45, 50) mapped against transaction data occurring on March 30th and 31st, 2021. This structure strongly suggests a record of transactions or trade data, which is often reported as supplementary data or in a raw format. Given the options, 'Financial Supplement Data (XLSX)' is the most appropriate category for raw, detailed transactional/numerical data that might accompany a primary filing, even if the format here is text-based representation of tabular data rather than an actual XLSX file. It is not a formal report (10-K, IR, ER) nor a specific announcement type (DIV, MANG, DIRS).
2021-04-06 English
Transactions in connection with share buy-back program
Transaction in Own Shares Classification · 100% confidence The document is a formal company announcement from Genmab regarding the execution of transactions under a share buy-back program. It provides specific details on the number of shares repurchased, the average price, and the total value for a specific period (March 29-31, 2021). This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2021-04-06 English
Transactions in connection with share buy-back program
Transaction in Own Shares Classification · 100% confidence The document is a company announcement detailing specific transactions executed under a share buy-back program. It provides a table of share counts, average prices, and total values for a specific period, and explicitly mentions the company's treasury shares. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2021-04-06 English
6-K
Foreign Filer Report
2021-03-30 English
Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
Regulatory Filings Classification · 95% confidence The document is a formal 'Company Announcement' from Genmab regarding the European marketing authorization of a drug (Kesimpta). It provides details on the regulatory approval, the clinical trial background (ASCLEPIOS), and the implications for the company. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a simple report publication notice (RPA) as it contains substantive information about the event itself. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2021-03-30 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.